<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04177862</url>
  </required_header>
  <id_info>
    <org_study_id>ANES-2019-28303</org_study_id>
    <nct_id>NCT04177862</nct_id>
  </id_info>
  <brief_title>Sublingual Sufentanil vs Intravenous Fentanyl for Acute Pain in the Ambulatory Surgery Center</brief_title>
  <official_title>Sublingual Sufentanil vs Intravenous Fentanyl for Acute Pain in the Ambulatory Surgery Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a single dose of sublingual sufentanil is as or
      more efficacious than a single dose of IV fentanyl in a post anesthesia care setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a level I randomized prospective outcomes study comparing two groups of patients.
      Upon arrival in the ambulatory surgery center (ASC) post-anesthesia care unit (PACU) if the
      patient has a pain score of 4 or greater they will then be randomized to one of two groups.
      Group 1 will receive 50 mcg of IV fentanyl and group 2 will receive 30 mcg of sublingual
      sufentanil. The primary outcome assessed will be time of readiness to discharge after arrival
      in the post-anesthesia care unit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 8, 2019</start_date>
  <completion_date type="Actual">January 31, 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time of Readiness to Discharge After Arrival in PACU</measure>
    <time_frame>1 day</time_frame>
    <description>The time (reported in minutes) from when the patient arrives in the PACU, right after surgery, to the time that all discharge criteria are met.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid Use After Intervention Until Discharge</measure>
    <time_frame>1 day</time_frame>
    <description>All doses of opioid medications (commonly, fentanyl and oxycodone) administered following initial dosage (sufentanil or fentanyl depending on study arm) will be converted to milligram morphine equivalents and summed for reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 day</time_frame>
    <description>Number of serious adverse events (grades 3, 4, and 5) experienced by each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea and vomiting (PONV)</measure>
    <time_frame>1 day</time_frame>
    <description>Number of participants in each arm who are treated for nausea and/or vomiting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supplemental Oxygen</measure>
    <time_frame>1 day</time_frame>
    <description>Number of participants in each arm who require supplemental oxygen therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Benefit of Analgesic Score (OBAS)</measure>
    <time_frame>1 day</time_frame>
    <description>Overall Benefit of Analgesic Score (OBAS) is a 7-item multi-dimensional survey that assesses analgesia benefits. Items are scored on a scale from 0 (minimal) to 4 (maximal). Total score is a sum of the 7 item scores with question 7 scored as 4 minus the patient reported number. Total scores range from 0 to 28 with lower scores representing greater benefit from analgesic therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Pain</condition>
  <condition>Pain, Acute</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Sublingual Sufentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of sublingual sufentanil for acute pain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Fentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose of IV fentanyl for acute pain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual Sufentanil</intervention_name>
    <description>30 mcg of sublingual sufentanil</description>
    <arm_group_label>Sublingual Sufentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Fentanyl</intervention_name>
    <description>50 mcg of IV fentanyl</description>
    <arm_group_label>IV Fentanyl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  undergoing outpatient ambulatory surgery

          -  recipient of general anesthesia

          -  pain score of 4 or greater in the PACU

        Exclusion Criteria:

          -  non-english speaking patients

          -  cancer surgeries

          -  patients who have allergy or intolerance to the study drugs or derivatives

          -  patients on chronic opioids (defined as daily opioids for 3 months or longer)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron M Berg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

